- 05/16/2019
- eisai to present data on oncology pipeline and products at 55th asco annual meeting
- 05/01/2019
- eisai buys out purdue rights to end collaboration
- 04/24/2019
- eisai to present latest data on lemborexant and perampanel at annual american academy of neurology meeting
- 03/29/2019
- data safety monitoring board recommends continuation of phase iii clinical studies of bace inhibitor elenbecestat in early alzheimer’s disease
- 03/22/2019
- initiation of phase iii clinical trial of ban2401 in early alzheimer’s disease
- 03/12/2019
- eisai and imbrium therapeutics announce u.s. fda filing acceptance of new drug application for lemborexant for the treatment of insomnia
- 02/13/2019
- eisai submits application in europe seeking approval for fycompa® as treatment for pediatric patients with epilepsy
- 02/04/2019
- eisai and purdue pharma present efficacy and safety data from second pivotal phase 3 study at the sleep research society’s conference: advances in sleep and circadian science
- 01/30/2019
- supplementary new drug application submitted in japan for fycompa® as monotherapy for partial-onset seizures, pediatric indication for partial-onset seizures, as well as new formulation
- 01/22/2019
- eisai listed as a global 100 most sustainable corporation for the fourth time
